Payment overview · 2025
General Payments
$1,133.10
32 reported records · 8 companies
Healthcare provider profile · identity verified
Daiyoon Lee, MD
Allopathic & Osteopathic Physicians|Family Medicine · SPRINGFIELD, MO · NPI 1477182798
Verified facts
What the public records show
CMS Open Payments records show Daiyoon Lee, MD received $1,133.10 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $232.72 | 20.5% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $155.17 | 13.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $148.02 | 13.1% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $138.90 | 12.3% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $136.63 | 12.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $135.00 | 11.9% | 3 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $121.66 | 10.7% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $65.00 | 5.7% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,133.10 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $137.18 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $136.63 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $135.00 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.77 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $121.69 | 1 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $121.66 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $120.45 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.95 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $65.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.48 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.57 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.66 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.48 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.59 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $1.72 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $1.72 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $1.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 28 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 479 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 253 | 71 |
| Alprazolam | Alprazolam | 251 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 86 |
| Simvastatin | Simvastatin | 231 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 219 | 65 |
| Gabapentin | Gabapentin | 208 | 55 |
| Losartan Potassium | Losartan Potassium | 204 | 64 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 190 | 35 |
| Lisinopril | Lisinopril | 187 | 58 |
| Tramadol Hcl | Tramadol Hcl | 167 | 44 |
| Metformin Hcl | Metformin Hcl | 166 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 55 |
| Meloxicam | Meloxicam | 139 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 138 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 37 |
| Omeprazole | Omeprazole | 124 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 34 |
| Trazodone Hcl | Trazodone Hcl | 103 | 28 |
| Clonazepam | Clonazepam | 98 | 16 |
| Montelukast Sodium | Montelukast Sodium | 98 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 97 | 31 |
| Ezetimibe | Ezetimibe | 91 | 33 |
| Lorazepam | Lorazepam | 88 | 19 |
| Glimepiride | Glimepiride | 87 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 86 | 30 |
| Furosemide | Furosemide | 77 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 70 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 23 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Carvedilol | Carvedilol | 66 | 19 |
| Eliquis | Apixaban | 64 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 62 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 16 |
| Allopurinol | Allopurinol | 52 | 17 |
| Finasteride | Finasteride | 50 | 16 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 48 | 15 |
| Metformin Hcl Er | Metformin Hcl | 47 | 18 |
| Alendronate Sodium | Alendronate Sodium | 46 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 14 |
| Bupropion Xl | Bupropion Hcl | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | 13 |
| Prednisone | Prednisone | 38 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 37 | 12 |
| Atenolol | Atenolol | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 12 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,133.10 · 32 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Azstarys, BREZTRI, CAPLYTA, COMIRNATY, KRYSTEXXA, NEFFY, NURTEC ODT, OTEZLA, PREVNAR 20, QULIPTA, REPATHA, REXULTI, UBRELVY, VRAYLAR, ZAVZPRET | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error